SAB Biotherapeutics (SABS) Shares Outstanding (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Shares Outstanding (Entity) data on file, last reported at $53.6 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 473.04% year-over-year to $53.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (up 473.04% YoY) and the FY2025 annual result came in at $47.7 million, up 410.13% from the prior year.
• Shares Outstanding (Entity) improved to $53.6 million in Q1 2026, from $47.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $53.6 million in Q1 2026 to a low of $4.4 million in Q1 2022.
• A 5-year average of $12.2 million and a median of $9.3 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 1131.63% — and 2025, when it advanced 0.67%.
• Tracing SABS's Shares Outstanding (Entity) over 5 years: stood at $5.1 million in 2022, then increased by 8.39% to $5.5 million in 2023, then soared by 69.22% to $9.3 million in 2024, then soared by 410.13% to $47.7 million in 2025, then rose by 12.37% to $53.6 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $53.6 million (Q1 2026), $47.7 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.